Other
Epithelioid Hemangioendothelioma
4
Pipeline Programs↗
3
Active Trials↗
4
Companies Involved↗
Epithelioid Hemangioendothelioma is an early-stage landscape with 4 programs across 4 companies. The most active players are CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis, Eisai.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 24
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
4
clinical trials
Completed1 · 25%
Recruiting1 · 25%
Active, not recruiting1 · 25%
Not yet recruiting1 · 25%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)